| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Endocrine System |
Recent Updates
Recently added Catalysts
XOMA Royalty Corporation
$40.17
0 (0%)
Last traded Jul 13, 2026. This price is not current.
C 53Pipeline Score Fair Value Pharma · Clinical
Market Cap
522.33 M
EPS
1.65
P/E Ratio
26.51 $
Value Trade
2.82 M
-0.45 %
Week
4.46 %
1 Month
70.35 %
3 Month
31.35 %
6 Month
31.6 %
5 Year
-99.18 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
6.71 M
52 Week Range
22.29 - 42.81
% held by Insiders
0.29 %
% held by Institutions
42.16 %
Enterprise Value
572.18 M
Total Shares
12.39 M
Short %
7.51 %
Float Shares
12.19 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for XOMA Royalty Corporation
438Total events
11Upcoming
162Tier-1 (high impact)
2012 – 2027Coverage
Upcoming catalysts 2
TBD
T2Timing Guidance
Subscribe to view catalyst details
TBD
T2R&D Day
Subscribe to view catalyst details
Event history 2
TBD
▲AcquiredCorporate
Subscribe to view catalyst details
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | canakinumab (Ilaris) sBLA | PDUFA Date | PDUFA | CRL | – | – | – |
— | canakinumab (Ilaris) sBLA | PDUFA Date | PDUFA | CRL | – | – | – |
— | canakinumab (Ilaris) sBLA | PDUFA Date | PDUFA | CRL | – | – | – |
Drug Pipeline Intelligence
C53
Pipeline Score $632M
Pipeline ValueFair Value
Valuation Signal5
Drugs Scored1.2x
rNPV / MCap Top 84%
Micro Cap (rank 150 of 933)
Percentile RankXOMA Royalty Corporation carries a moderate pipeline score (53/100), with $3.2B risk-adjusted pipeline value, led by XOMA 052 in Diabetes Mellitus Type 1 (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XOMA 052 Small molecule | Diabetes Mellitus Type 1 | Phase 2 | NCT01788033 | 23% | $2.5B | COMPLETED | 22 | - | - | Sep 1, 2013 | - | Feb 11, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XOMA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XOMA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How XOMA ranks across every disease it competes inCompetitive Position is a premium feature
See how XOMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial